Hormonal
Obese visceral fat inflammation is an initially protective adaptive response to restore metabolic homeostasis, but becomes detrimental when structural damage and senescence trigger chronic immune infiltration.
Understand that inflammation in fat tissue is not just 'damage' but a complex signal. In the early stages of weight gain, it helps your body adapt to storing more energy. However, if this stress continues, the system breaks down, leading to structural damage and chronic disease. The goal is not to blindly suppress inflammation but to address the root cause: excess nutrient influx and adipocyte overload.
Obese visceral fat inflammation can be viewed as an initially protective response in order to cope with excess ambient nutrients and restore tissue homeostasis but may contribute to tissue damage at a later stage.
Why this rating
The paper is a comprehensive review synthesizing extensive animal and human observational data, though it lacks direct interventional clinical trial evidence for reversing the process.
Source
Obese visceral fat tissue inflammation: from protective to detrimental?
Hubert Kolb · BMC Medicine · 2022
DOI 10.1186/s12916-022-02672-y
More from this paper
- Adipocyte hypertrophy and subsequent endoplasmic reticulum stress trigger a pro-inflammatory response (metaflammation) that initially preserves metabolic control by promoting lipolysis and tissue remodeling.Good
- Chronic structural damage in visceral fat, characterized by adipocyte death and senescence, shifts inflammation from protective to detrimental by recruiting circulating immune cells and causing fibrosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →